Par Drugs and Chemicals Limited — Board Meeting, 14-02-2025: Outcome of Board Meeting

The Board of Directors has approved the unaudited financial results for the quarter and nine months ended December 31, 2024. Revenue for the quarter stands at ₹2,138.11 Cr, with a profit before tax of ₹77.24 Cr. The total expenses for the period amount to ₹2,088.06 Cr, leading to a profit after tax of ₹57.80 Cr. Additionally, an Investor grievances report and a Corporate Governance Report were reviewed. Advertisements regarding the financial results will be published in newspapers. Shareholders should note the company's continuous focus on compliance and governance as part of its strategic direction.